An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl45386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Zhen Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Proto-Oncogene Proteins c-myc, Anoikis, Drug Resistance, Neoplasm. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Zhuang Autonomous Region Health Commission scientific research project.
Abstract (Originalsprache)
Background
Resistance to anoikis is a critical mechanism that enables metastatic dissemination. Abrogation of this cellular safeguard is therefore a hallmark of aggressive cancer progression. Despite the importance of anoikis, there are still few biomarkers among anoikis-related genes (ARGs) that could aid in the prognostication of bladder cancer (BC) patients and potentially serve as drug targets.
Methods
This study leveraged bioinformatics analyses of publicly available BC datasets to evaluate the association between differentially expressed ARGs and patient prognosis. Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was employed to build a novel prognostic signature model for BC based on ARGs. This model was also used to predict the response of BC to anticancer drugs. Additionally, immunohistochemistry was used to assess expression of the key gene, MYC, in BC samples obtained from patients undergoing surgery and from those receiving immune checkpoint inhibitor (ICI) therapy.
Results
The ARG-based signature, developed and validated through the analysis of public databases, was an independent predictor of patient outcomes. Furthermore, it effectively stratified patients into two cohorts (high- and low-risk), allowing investigation of differential drug sensitivities. The risk stratification model identified 10 ARGs (IGF1, CALR, E2F1, MYC, PLK1, SATB1, FASN, ID2, RAC3, and GKN1) as potential therapeutic vulnerabilities. Notably, MYC was identified as a central hub gene within the ARG signature. Elevated MYC expression was strongly associated with worse prognosis in muscle-invasive bladder cancer (MIBC), and with a diminished response to immunotherapy.
Conclusion
This work demonstrated significant prognostic value for the ARG-based model. Specific ARGs could function as crucial biomarkers for patient outcome, while simultaneously offering new avenues for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China.
- Department of Radiology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China.
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, 530021 Nanning, Guangxi, China.
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, 5300…
Förderung
- Guangxi Zhuang Autonomous Region Health Commission scientific research project
Zitieren
APA
Tang, Z., Peng, J., Pan, X., Kong, Y., Lin, H., Wei, S., Zhan, Y., & Zeng, S. (2025). An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl45386
Vancouver
Tang Z, Peng J, Pan X, Kong Y, Lin H, Wei S, et al. An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl45386
BibTeX
@article{Tang2025,
author = {Tang, Zhen and Peng, Jiao and Pan, Xiaoyu and Kong, Yuefeng and Lin, Haisong and Wei, Suchun and Zhan, Yi and Zeng, Siping},
title = {An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl45386}
}
EUVIMED